We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical features and oncological outcomes of bladder cancer microsatellite instability.
- Authors
Nagakawa, Shohei; Shiota, Masaki; Takamatsu, Dai; Tsukahara, Shigehiro; Mastumoto, Takashi; Blas, Leandro; Inokuchi, Junichi; Oda, Yoshihiro; Eto, Masatoshi
- Abstract
Objectives: Excellent anticancer effect for solid tumors with microsatellite instability (MSI)‐high by anti‐PD‐1 antibody has been reported. In this study, we investigated the clinical impact of MSI status in bladder cancer. Methods: This study included 205 Japanese patients who underwent transurethral resection for bladder cancer between 2005 and 2021. The prevalence rates of microsatellite stable (MSS), MSI‐low (MSI‐L), and MSI‐high (MSI‐H) were determined using molecular testing. We examined the association of MSI status (MSS versus MSI‐L/H) with clinicopathological characteristics and oncological outcomes. Results: MSI‐L/H tumors were associated with higher T‐category in non‐muscle invasive bladder cancer (NMIBC). Additionally, MSI‐L/H tumors were associated with a higher risk of intravesical recurrence in NMIBC patients treated with intravesical bacillus Calmette‐Guérin (BCG) but not with non‐BCG therapy. Conclusions: This study suggested that the MSI status might serve as a predictive marker for intravesical recurrence after BCG intravesical therapy in NMIBC and highlighted an unmet need for an alternative treatment in patients with MSI‐L/H tumors.
- Subjects
BLADDER cancer; INTRAVESICAL administration; NON-muscle invasive bladder cancer; MICROSATELLITE repeats; TRANSURETHRAL resection of bladder; BCG immunotherapy; CANCER prognosis
- Publication
International Journal of Urology, 2024, Vol 31, Issue 4, p438
- ISSN
0919-8172
- Publication type
Article
- DOI
10.1111/iju.15370